Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
35.18
-1.89 (-5.10%)
May 18, 2026, 4:00 PM EDT - Market closed
Rapport Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Rapport Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $54.7. The average 1-year stock price forecast is 55.49% higher than the current stock price, while the lowest is $40 (+13.70%) and the highest is $80 (+127.40%).
Price Target: $54.7 (+55.49%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rapport Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +50.65% | May 8, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +50.65% | Apr 22, 2026 |
| BTIG | BTIG | Strong Buy Maintains $47 → $53 | Strong Buy | Maintains | $47 → $53 | +50.65% | Mar 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $43 → $46 | Buy | Maintains | $43 → $46 | +30.76% | Mar 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $43 | Buy | Initiates | $43 | +22.23% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
11.66M
Revenue Next Year
n/a
from 11.66M
EPS This Year
-3.42
from -2.86
EPS Next Year
-4.42
from -3.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 21.0M | n/a | ||||||
| Avg | 11.7M | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.50 | -3.14 | ||||||
| Avg | -3.42 | -4.42 | ||||||
| Low | -4.48 | -5.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.